The primary aim of the present trial was to compare the effects of liraglutide 1.8 and 3.0 mg, the maximum approved dose in treatment of type 2 diabetes and the intended clinical dose in weight management, respectively, on gastric emptying in obese individuals without T2DM, with the focus on demonstrating equivalence between the two doses over a 5-h period, in order to support that no dose adjustment of concomitantly administered oral medications would be required during treatment with liraglutide 3.0 mg
Wegovy and Zepbound can cost $1,000 or more per month without insurance
This method can be particularly potent because it ensures that the skin receives a consistent dose of the ingredient, maximizing its efficacy
Siddiqui K, Joy SS, George TP, Mujammami M, Alfadda AA (2020) Potential role and excretion level of urinary transferrin, KIM-1, RBP, MCP-1 and NGAL markers in diabetic nephropathy